Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Aim: To assess the comparative effects of glucose‐lowering drugs (GLDs) on the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). Methods: We systematically searched Cochrane Central Register of Controlled Trials, PUBMED and EMBASE from inception to January 17, 2017 to identify randomized controlled trials (RCTs) that reported DR events among T2DM patients receiving any GLD. Random‐effects pairwise and network meta‐analyses were performed to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Results: A total of 37 independent RCTs with 1806 DR events among 100 928 patients with T2DM were included. The mean duration of diabetes was 8.7 years and mean baseline HbA1c was 8.2% (SD, 0.5%). Our network meta‐analysis found that DPP‐4i (OR, 1.20; 95% CI, 0.87‐1.65), GLP‐1RA (OR, 1.19; 95% CI, 0.94‐1.52) and SGLT2 inhibitors (OR, 0.79; 95% CI, 0.49‐1.28) were not associated with a higher risk of DR than placebo; however, a significantly increased risk of DR was associated with DPP‐4i in the pairwise meta‐analysis (OR, 1.27; 95% CI, 1.05‐1.53). Sulfonylureas, on the other hand, were associated with a significantly increased risk of DR compared to placebo (OR, 1.67; 95% CI, 1.01‐2.76). Conclusions: Current evidence indicates that the association between DPP‐4i, GLP‐1RA or SGLT2 inhibitors and risk of DR remains uncertain in patients with T2DM. Some evidence suggests that sulfonylureas may be associated with increased risk of DR. However, given that DR events were not systematically assessed, these effects should be explored further in large‐scale, well‐designed studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Only 2 trials that predefined and adjudicated DR events had a low risk of other bias.(8,14) 3.”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“To check the assumption of consistency in the entire network, a design-by-treatment interaction model involving the χ(2) test was used.(23) Finally, a comparison-adjusted funnel plot was used to assess small study effects within a network of interventions.”
MethodSalanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729 · cited 1×
“In this study, larger SUCRA probabilities indicate lower risk of DR events.(20) The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to investigate between-study heterogeneity in the network meta-analysis.”
MethodAntonetti, D. A., Klein, R., & Gardner, T. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1005073 · Cited by 1,659
White, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114
Turner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys041 · Cited by 837 · cited 1×
“The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to investigate between-study heterogeneity in the network meta-analysis.(21) To check for the presence of inconsistency, a loop inconsistency-specific approach was introduced to evaluate the difference between direct and…”
MethodEvaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576 · cited 1×
“To check for the presence of inconsistency, a loop inconsistency-specific approach was introduced to evaluate the difference between direct and indirect estimates for a specific comparison.(22) To check the assumption of consistency in the entire network, a design-by-treatment interaction model involving the χ(2) test…”
MethodChaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521 · cited 1×
“Finally, a comparison-adjusted funnel plot was used to assess small study effects within a network of interventions.(24) We performed a regression analysis to examine the relationship between trial characteristics and effect size using the following factors: duration of diabetes, difference in change in glycaemic cont…”
MethodHernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130
Research works printed but not linked: 52
- 10.2337/dc12-0863 · DOI · Paper page
- 10.1001/jama.298.8.902 · DOI · Paper page
- 10.1056/NEJM199309303291401 · DOI · Paper page
- 10.1136/bmj.321.7258.405 · DOI · Paper page
- 10.1056/NEJMoa0806470 · DOI · Paper page
- 10.2337/dc16-2641 · DOI · Paper page
- 10.1016/j.ajo.2008.10.016 · DOI
- 10.1001/archinternmed.2012.1938 · DOI · Paper page
- 10.1016/j.lfs.2016.01.042 · DOI
- JPT H, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 510
- 10.1002/sim.1186 · DOI · Paper page
- 10.1038/ajg.2008.22 · DOI · Paper page
- 10.1056/NEJMoa1612917 · DOI · Paper page
- 10.1111/j.1464-5491.2011.03387.x · DOI · Paper page
- 10.1007/s40261-013-0107-8 · DOI
- 10.2337/dc12-2718 · DOI · Paper page
- 10.2337/dc12-1365 · DOI · Paper page
- 10.1007/s00125-015-3795-1 · DOI · Paper page
- 10.1111/j.2040-1124.2011.00128.x · DOI · Paper page
- 10.1111/dom.12188 · DOI · Paper page
- 10.1016/S0140-6736(13)60683-2 · DOI · Paper page
- 10.1016/S2213-8587(14)70120-2 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01385.x · DOI · Paper page
- 10.2337/dc13-2855 · DOI · Paper page
- 10.1111/dom.12540 · DOI · Paper page
- 10.2337/dc14-0876 · DOI · Paper page
- 10.1007/s00125-014-3360-3 · DOI
- 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
- 10.1111/1753-0407.12357 · DOI
- 10.1111/jdi.12457 · DOI · Paper page
- 10.1111/dom.12121 · DOI · Paper page
- 10.1111/j.2040-1124.2011.00103.x · DOI
- 10.2337/dc14-0001 · DOI · Paper page
- 10.1016/S0140-6736(10)60307-8 · DOI · Paper page
- 10.2337/dc14-0024 · DOI · Paper page
- 10.1016/j.bbadis.2014.04.013 · DOI
- 10.1111/j.1463-1326.2011.01548.x · DOI
- 10.1167/iovs.15-19006 · DOI · Paper page
- 10.1007/s00125-017-4388-y · DOI
- 10.1186/1475-2840-13-19 · DOI
- 10.1186/1475-2840-12-59 · DOI
- 10.1161/ATVBAHA.116.307930 · DOI
- 10.2337/db16-1364 · DOI · Paper page
- 10.1016/j.diabres.2013.12.041 · DOI
- 10.1016/j.diabres.2011.08.017 · DOI
- 10.1186/s12933-017-0510-1 · DOI · Paper page
- 10.1038/ki.2014.246 · DOI
- 10.1016/S2213-8587(14)70256-6 · DOI
- 10.1056/NEJMoa0802987 · DOI · Paper page
- 10.1007/s00125-009-1457-x · DOI · Paper page
- 10.1001/archophthalmol.2009.310 · DOI
- Gower EW, 2017, Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD EYE Study, Am J Ophthalmol
Cited by
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
Gaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95
Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., Jackson, T. L., Wilding, J. P. H., & Alam, U. (2024) · Diabetologia · doi:10.1007/s00125-024-06132-5 · Cited by 73
“This has been further supported by a systematic review and meta-analysis which showed no increase in diabetic retinopathy risk in the GLP1-ra groups [31].”
ResultYoshida, Y., Joshi, P., Barri, S., Wang, J., Corder, A. L., O'Connell, S. S., & Fonseca, V. A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108255 · Cited by 65
Metadata
- Authors
- Tang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-02-23
- Volume
- 20
- Issue
- 5
- Pages
- 1262-1279
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2789501881
- Cited by
- 78
- References
- 20
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.